Thrombin-Activatable Fibrinolysis Inhibitor

Thrombin activatable fibrinolysis inhibitor (TAFI) is a zymogene that can inhibit fibrinolysis through the removal of the carboxy-terminal lysine and arginine residues from partially degraded fibrin polymers. In addition, TAFI has a suppressor effect on conversion of inactive plasminogen to plasmin. TAFI may play a central role in thrombosis and fibrinolysis due to its ability to slow fibrin clot lysis. TAFI plays a role in CVD, inflammation and may contribute to thromboembolic manifestations in the course of multiple myeloma.

Swiss-Prot Accession Number: Q96IY4